Literature DB >> 20404807

Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.

Susan K Mathai1, Mridu Gulati, Xueyan Peng, Thomas R Russell, Albert C Shaw, Ami N Rubinowitz, Lynne A Murray, Jonathan M Siner, Danielle E Antin-Ozerkis, Ruth R Montgomery, Ronald A S Reilkoff, Richard J Bucala, Erica L Herzog.   

Abstract

Profibrotic cells derived from circulating CD14+ monocytes include fibrocytes and alternatively activated macrophages. These cells are associated with interstitial lung disease (ILD) and are implicated in the pathogenesis of systemic sclerosis (SSc); however, the simultaneous presence of profibrotic cells and their associated mediators in the circulation of these patients has not been defined. We hypothesized that monocytes from patients with SSc-related ILD (SSc-ILD) would show profibrotic characteristics when compared with normal controls. We recruited patients with SSc-ILD (n=12) and normal controls (n=27) and quantified circulating collagen-producing cells by flow cytometry for CD45 and pro-collagen I. The in vitro activation potential of CD14+ monocytes in response to lipopolysaccharide was assessed using flow cytometry for CD163, and by ELISA for CCL18 and IL-10 secretion. Profibrotic mediators in plasma were quantified using Luminex-based assays. The concentration of circulating collagen-producing cells was increased in the SSc-ILD patients when compared with controls. These cells were composed of both CD34+ fibrocytes and a population of CD34+CD14+ cells. Cultured CD14+ monocytes from SSc-ILD patients revealed a profibrotic phenotype characterized by expression of CD163 and by enhanced secretion of CCL18 and IL-10 in response to proinflammatory activation. Plasma levels of IL-10, MCP-1, IL-1RA, and TNF levels were significantly elevated in the plasma of the SSc-ILD cohort. Subgroup analysis of the normal controls revealed that unlike the subjects < or =35 years, subjects > or =60 years old showed higher levels of circulating CD34+CD14+ cells, collagen-producing CD14+ monocytes, CD163+ monocytes, IL-4, IL-10, IL-13, MCP-1, and CCL18. These data indicate that the blood of patients with SSc-ILD and of healthy aged controls is enriched for fibrocytes, profibrotic monocytes, and fibrosis-associated mediators. Investigations defining the factors responsible for this peripheral blood profile may provide new insight into SSc-ILD as well as the pathophysiology of aging.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20404807      PMCID: PMC3682419          DOI: 10.1038/labinvest.2010.73

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  51 in total

1.  Effects of an exercise intervention on immunologic parameters in frail elderly nursing home residents.

Authors:  Zoher F Kapasi; Joseph G Ouslander; John F Schnelle; Michael Kutner; John L Fahey
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2003-07       Impact factor: 6.053

Review 2.  Monocyte and macrophage heterogeneity.

Authors:  Siamon Gordon; Philip R Taylor
Journal:  Nat Rev Immunol       Date:  2005-12       Impact factor: 53.106

3.  Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease.

Authors:  Borna Mehrad; Marie D Burdick; David A Zisman; Michael P Keane; John A Belperio; Robert M Strieter
Journal:  Biochem Biophys Res Commun       Date:  2006-12-11       Impact factor: 3.575

4.  Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation.

Authors:  Frank D'Ovidio; Marco Mura; Melanie Tsang; Thomas K Waddell; Michael A Hutcheon; Lianne G Singer; Denis Hadjiliadis; Cecilia Chaparro; Carlos Gutierrez; Andrew Pierre; Gail Darling; Mingyao Liu; Shaf Keshavjee
Journal:  J Thorac Cardiovasc Surg       Date:  2005-05       Impact factor: 5.209

5.  A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes.

Authors:  K Hieshima; T Imai; M Baba; K Shoudai; K Ishizuka; T Nakagawa; J Tsuruta; M Takeya; Y Sakaki; K Takatsuki; R Miura; G Opdenakker; J Van Damme; O Yoshie; H Nomiyama
Journal:  J Immunol       Date:  1997-08-01       Impact factor: 5.422

6.  Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis.

Authors:  Norihiko Sakai; Takashi Wada; Hitoshi Yokoyama; Martin Lipp; Satoshi Ueha; Kouji Matsushima; Shuichi Kaneko
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-11       Impact factor: 11.205

Review 7.  Circulating fibrocytes: collagen-secreting cells of the peripheral blood.

Authors:  Timothy E Quan; Shawn Cowper; Sou-Pan Wu; Linda K Bockenstedt; Richard Bucala
Journal:  Int J Biochem Cell Biol       Date:  2004-04       Impact factor: 5.085

8.  Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma.

Authors:  Matthias Schmidt; Guo Sun; Martin A Stacey; Luca Mori; Sabrina Mattoli
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

Review 9.  Fibrocytes in lung disease.

Authors:  Brigitte N Gomperts; Robert M Strieter
Journal:  J Leukoc Biol       Date:  2007-06-05       Impact factor: 4.962

10.  Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma.

Authors:  Yan Ding; Elissa A Boguslawski; Bree D Berghuis; John J Young; Zhongfa Zhang; Kim Hardy; Kyle Furge; Eric Kort; Arthur E Frankel; Rick V Hay; James H Resau; Nicholas S Duesbery
Journal:  Mol Cancer Ther       Date:  2008-03-04       Impact factor: 6.261

View more
  101 in total

1.  Fibrocyte accumulation in the lungs of cystic fibrosis patients.

Authors:  Rajesh K Kasam; Prathibha R Gajjala; Anil G Jegga; Jennifer A Courtney; Scott H Randell; Elizabeth L Kramer; John P Clancy; Satish K Madala
Journal:  J Cyst Fibros       Date:  2020-06-25       Impact factor: 5.482

2.  Fibrocytes Regulate Wilms Tumor 1-Positive Cell Accumulation in Severe Fibrotic Lung Disease.

Authors:  Vishwaraj Sontake; Shiva K Shanmukhappa; Betsy A DiPasquale; Geereddy B Reddy; Mario Medvedovic; William D Hardie; Eric S White; Satish K Madala
Journal:  J Immunol       Date:  2015-09-14       Impact factor: 5.422

Review 3.  Fibrocytes at 20 Years.

Authors:  Rick Bucala
Journal:  Mol Med       Date:  2015-10-27       Impact factor: 6.354

Review 4.  Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence?

Authors:  Giuseppina Stifano; Romy Beatriz Christmann
Journal:  Curr Rheumatol Rep       Date:  2016-01       Impact factor: 4.592

5.  Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension.

Authors:  Min Li; Suzette R Riddle; Maria G Frid; Karim C El Kasmi; Timothy A McKinsey; Ronald J Sokol; Derek Strassheim; Barbara Meyrick; Michael E Yeager; Amanda R Flockton; B Alexandre McKeon; Douglas D Lemon; Todd R Horn; Adil Anwar; Carlos Barajas; Kurt R Stenmark
Journal:  J Immunol       Date:  2011-08-03       Impact factor: 5.422

Review 6.  Paracrine functions of fibrocytes to promote lung fibrosis.

Authors:  Kathryn R Kleaveland; Bethany B Moore; Kevin K Kim
Journal:  Expert Rev Respir Med       Date:  2014-01-22       Impact factor: 3.772

7.  The lung macrophage: a Jack of all trades.

Authors:  Alexander V Misharin; G R Scott Budinger; Harris Perlman
Journal:  Am J Respir Crit Care Med       Date:  2011-09-01       Impact factor: 21.405

8.  Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.

Authors:  Lili Jiang; Youlian Wang; Qinglin Peng; Xiaoming Shu; Guochun Wang; Xiaomu Wu
Journal:  Clin Rheumatol       Date:  2019-02-09       Impact factor: 2.980

Review 9.  Fibrocytes in Fibrotic Diseases and Wound Healing.

Authors:  Gerrit Grieb; Richard Bucala
Journal:  Adv Wound Care (New Rochelle)       Date:  2012-02       Impact factor: 4.730

10.  Semaphorin 7a+ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-β1-induced pulmonary fibrosis.

Authors:  Ronald A Reilkoff; Hong Peng; Lynne A Murray; Xueyan Peng; Thomas Russell; Ruth Montgomery; Carol Feghali-Bostwick; Albert Shaw; Robert J Homer; Mridu Gulati; Aditi Mathur; Jack A Elias; Erica L Herzog
Journal:  Am J Respir Crit Care Med       Date:  2012-12-06       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.